Icahn School of Medicine at Mount Sinai Archives

Considerations for the Clinical Impact of Next Generation Imaging in Prostate Cancer

Posted by Ashley E. Ross, MD, PhD | Jan 2020

Ashley Ross, MD, PhD, Executive Medical Director of the Mary Crowley Cancer Research Center in Dallas, discusses the current and potential impact of PSMA PET imaging on the identification and treatment of localized prostate cancer. He notes how PET PSMA and fluciclovine imaging can increase the accuracy of detecting clinically significant localized disease. Dr. Ross further discusses how PET imaging assists in risk stratification of candidates for treatment of HSPC, nmCRPC using salvage local therapy, metastasis-directed therapy, or intensification of systemic therapy. He also discusses how PET imaging can help identify candidates for cure with local treatments.

Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Con Argument

Posted by David Utz | Jan 2020

Robert E. Donohue, MD, argues against urologists adhering to the National Comprehensive Cancer Network (NCCN) Prostate Cancer Screening and Early Detection Guidelines. He proposes his own definitive answers to controversial questions relating to the use of digital rectal exams and PSA tests in baseline evaluation, indications for biopsy and biopsy technique, the age for initiation and discontinuation of testing, the frequency of testing, screening in high-risk populations, and which biomarkers to use.

Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Pro Argument

Posted by A. Karim Kader, MD, PhD | Jan 2020

A. Karim Kader, MD, PhD, argues that although PSA-based prostate cancer screening is flawed, urologists should adhere to the National Comprehensive Cancer Network (NCCN) Prostate Cancer Screening and Early Detection Guidelines. He outlines how, in order to avoid overdiagnosis and other issues, urologists can be more judicious as to which patients are offered screening, biopsy, and treatment, while not abandoning the use of PSA as a marker for prostate cancer altogether.

Image-Guided Biopsy and Treatment

Posted by Daniel Margolis, MD | Jan 2020

Daniel Margolis, MD, discusses the evolving role of imaging in biopsy and focal therapy guidance. He reviews the advantages of current image-targeting techniques, including MRI/ultrasound fusion and MRI in-bore targeting.

Standard Treatment for Advanced Prostate Cancer

Posted by David M. Nanus, MD | Jan 2020

David M. Nanus, MD, reviews the approvals for and evidence surrounding therapies to treat advanced prostate cancer. He focuses on taxane chemotherapy, androgen deprivation therapy, androgen receptor pathway inhibitors, bone-targeted therapy, and common approaches in tumor immunotherapy.